Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLMD 
Galmed Pharmaceuticals Ltd (GLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: GLMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.63% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.34M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.5 | 52 Weeks Range 1.15 - 3.61 | Updated Date 10/31/2025 |
52 Weeks Range 1.15 - 3.61 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.21% | Return on Equity (TTM) -53.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3998608 | Price to Sales(TTM) - |
Enterprise Value -3998608 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.32 | Shares Outstanding 5479231 | Shares Floating 5229815 |
Shares Outstanding 5479231 | Shares Floating 5229815 | ||
Percent Insiders 1.19 | Percent Institutions 1.42 |
Upturn AI SWOT
Galmed Pharmaceuticals Ltd
Company Overview
History and Background
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases. Founded in 2000, it has primarily focused on its lead compound, Aramchol, targeting NASH and fibrosis.
Core Business Areas
- NASH and Fibrosis: Galmed's primary focus is on developing Aramchol for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical industry. The company structure involves departments such as research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Aramchol: Aramchol is Galmed's lead investigational drug for the treatment of NASH. Market share data is not applicable as the product is not yet approved. Key competitors include Madrigal Pharmaceuticals (MDGL) with Resmetirom, Akero Therapeutics (AKRO) with Efruxifermin, and Viking Therapeutics (VKTX) with VK2809.
Market Dynamics
Industry Overview
The NASH market is a rapidly growing area with a high unmet medical need. Numerous companies are developing potential therapies.
Positioning
Galmed is positioned as a company developing a novel therapy for NASH. Its competitive advantage, if approved, would be efficacy and safety profile compared to existing treatments. But the company did announced trial failure with Aramchol, so its future is uncertain.
Total Addressable Market (TAM)
The NASH market is projected to reach billions of dollars annually. Galmed's potential success depends on Aramchol's approval and market penetration. Before the trail failure, the TAM was projected to be close to $50 billion by 2030.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidate (Aramchol)
- Experienced management team
- Focus on a high unmet medical need
Weaknesses
- Single product pipeline (Aramchol)
- Dependence on clinical trial outcomes
- Limited financial resources
- Recent Phase 3 failure
Opportunities
- Potential for partnerships and collaborations
- Market expansion into related liver diseases
- Advancements in diagnostic tools for NASH
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and approval delays
- Clinical trial failures or adverse events
- Patent expirations
Competitors and Market Share
Key Competitors
- MDGL
- AKRO
- VKTX
Competitive Landscape
Galmed faces significant competition from larger, well-funded pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety of Aramchol.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, primarily focusing on advancing Aramchol through clinical trials.
Future Projections: Future growth is highly dependent on the success of Aramchol and any potential future drug candidates. Analysts' projections are subject to change based on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives have included completing and analyzing clinical trials for Aramchol.
Summary
Galmed Pharmaceuticals is a high-risk, high-reward clinical-stage biopharmaceutical company focused on NASH. The company's success hinges on clinical trials and regulatory approvals for Aramchol. The recent phase 3 failure will greatly impact the companies future. Competition in the NASH market is intense, and Galmed needs to navigate these challenges effectively to generate value for shareholders.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- ClinicalTrials.gov
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. The information provided is based on available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galmed Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-13 | Co-Founder, President, CEO & Chairman Mr. Allen Baharaff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://galmedpharma.com |
Full time employees 3 | Website https://galmedpharma.com | ||
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.